Pharma BD Deal Intelligence
On October 8, 2026 Roche Holding AG entered a research collaboration and exclusive license agreement with Hangzhou-based Defand Therapeutics covering molecular glue degraders for oncology and immunology. Defand will apply its degrader screening platform to identify candidates and advance programs to agreed research-and-development stages, after which Roche assumes further preclinical and clinical development and holds exclusive global commercialization rights. Trade press reports total potential value close to $1 billion with an upfront payment of under $10 million, meaning nearly all of the headline figure is milestone-contingent; Roche did not disclose specific terms. The agreement is Roche's fourth China collaboration in seven weeks.
← Browse all deals · How we score deals
More: 2026 deals · Roche Holding AG deals